Novo Nordisk's Drug Prices and Production Capacity in Focus -- Earnings Preview
Novo Nordisk's blockbuster GLP-1 drugs to treat type 2 diabetes and obesity, including Wegovy and Ozempic, continued to drive the company's growth in the quarter, Sydbank senior analyst Soren Lontoft Hansen said in a note.
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...
Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...
Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...
Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Tuesday after the company reported strong third-quarter ...
Piper Sandler analyst Korinne Wolfmeyer raised the firm’s price target on Hims & Hers to $21 from $18 and keeps a Neutral rating on ...
Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong ...
uk.investing.com on MSN17h
Hims & Hers Health shares spike after group posts earnings beat, raises guidanceHims&Hers Health (NYSE:HIMS) reported third-quarter earnings that surpassed analyst expectations and raised its full-year guidance, driven by strong subscriber growth and improving profitability.
Ladies and gentlemen, thank you for standing by. My name is Krista and I will be your conference operator today. At this time, I would like to welcome everyone to His & Hers third-quarter earnings ...
Hims & Hers Health reported its third-quarter results after Monday's closing bell. Here's a look at the details from the ...
Hims & Hers Health raised its full-year outlook after it swung to a profit in the third quarter boosted by a tax benefit and consumer demand for weight-loss drugs.
Stocktwits on MSN20h
Hims & Hers Soars Pre-Market After Analysts Boost Price Targets On Strong Q3 PerformanceHims & Hers Health Inc. ($HIMS) rallied nearly 9% in pre-market trading on Tuesday, following the company’s third-quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback